CN104922698B - Human stem cell growth parenteral solution and preparation method thereof - Google Patents
Human stem cell growth parenteral solution and preparation method thereof Download PDFInfo
- Publication number
- CN104922698B CN104922698B CN201510298631.0A CN201510298631A CN104922698B CN 104922698 B CN104922698 B CN 104922698B CN 201510298631 A CN201510298631 A CN 201510298631A CN 104922698 B CN104922698 B CN 104922698B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- parenteral solution
- solution
- citrate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to human stem cell growth parenteral solutions and preparation method thereof, the parenteral solution can reach the technique effect of sustained release, reduce the medicining times of patient, improve compliance, which can be used for preparing treatment anaemia, being promoted and recovered of chemicotherapy and the postoperative hematopoiesis function of bone-marrow transplantation, ex vivo expansion of stem cell, gene therapy medicament and the application in terms of epidermal cell metabolism is promoted, repair aging and damage the cosmetics such as Skin Cell, delaying skin aging etc..
Description
Technical field
The invention belongs to technical field of pharmaceutical biotechnology, and in particular to the parenteral solution of human stem cell growth.
Background technology
Stem cell factor（SCGF）It is a kind of acidoglycoprotein generated by the stroma cell in bone marrow microenvironment, it
It is a kind of important hematopoietic cytokine, mainly acts on the candidate stem cell of early stage and primitive hematopoietic progenitor cells, promote its increasing
It grows and breaks up, maintaining hematopoietic cell survival, promoting hematopoietic cell proliferation and differentiation, regulate and control the growth and development of each system's hematopoietic cell
In play an important role.With going deep into for research, it has been found that human stem cell growth has the function of various biological, can be wide
It is general to be applied to the numerous areas such as biological medicine, fine chemistry industry.Particularly stem cell grows rapidly in recent years, utilizes stem cells technology
Carrying out disease treatment has very big development prospect, has great meaning especially for hemopathic treatment.Bone-marrow transplantation
Have become with hematopoietic stem cell transplantation and a kind of hemopathic main means are treated in modern medicine, but also there is blood to match somebody with somebody
Type is difficult, stem cell population is few, the problems such as amplification difficulty.It if can be from patient or other groups of the people identical with its distribution type
Knit and adult stem cell isolated in organ, in vitro realize hematopoietic cell directed differentiation, rapid amplifying, this will pair and hematopoiesis
Stem cell transplantation is of great significance.But natural soluble type SCF is little in human body and animal in-vivo content, in blood
Concentration is 3.3ng/ml, therefore sufficient amount sample can not possibly be isolated and purified from natural tissues, carries out laboratory and clinical practice is ground
Study carefully.Albumen and polypeptide are all preferable drug in terms of many treatments, however these beneficial effectiveness may finally be limited to pass
Pass the difficulty of albumen.In oral and cutaneous penetration, bioavilability is usually very low, and half-life short.By albumen and more
Peptide medicament, which is prepared into sustained release preparation, can reduce frequency of use, improve the compliance of patient.Injection sustained release is in the world at present
System mainly has microballoon, liposome and implant.To albumen and polypeptide drug, the microballoon prepared by biodegradable material is
Quite preferable drug-loading system.
For protein medicaments, complicated technique, violent condition may all cause the forfeiture of protein active.At present
Market has no the parenteral solution with the nucleotide sequence shown in SEQ ID NO.1.
The content of the invention
It is an object of the present invention to provide a kind of parenteral solutions of the nucleotide sequence with shown in SEQ ID NO.1, apply for people's will
Outer discovery, when the parenteral solution that the nucleotide sequence shown in PEG the and SEQ ID NO.1 using particular types and ratio obtains
It is with good stability, there is the nucleotide sequence shown in SEQ ID NO.1（The sequence is applicant January 17 in 2012
Filed in day, claimed sequence in the patent of invention of Application No. 201210016142.8, herein by the content of the patent
It is all incorporated in the present application, specific prepare is not repeated to describe with preservation）.
Nucleotide sequence parenteral solution shown in a kind of SEQ ID NO.1, including the nucleotides sequence shown in SEQ ID NO.1
Row, human albumin, citrate buffer, sodium chloride and PEG, pH are to 4.5-6.5.
Wherein, the PEG be PEG400,600,800, preferably PEG600, dosage 10-20%（w/v）, the SEQ ID
Nucleotides sequence shown in NO.1 is classified as 1-3 mol/L, and citrate content maintains pH to 4.5-6.5, and preferably 5.5, sodium chloride
Dosage is maintenance ionic strength in 0.1-0.3 mol/L, human albumin（w/v）In 3-5%.
The parenteral solution of the present invention can be prepared as follows：
(1) water for injection citrate is adjusted into pH to 4.5-6.5, adds in human albumin, stirring；
(2) by the solution of the nucleotide sequence step 1 shown in SEQ ID NO.1, PEG is added in, is uniformly mixed,
When 2-5 DEG C of placement 10 is small, sodium chloride is added in, makes solution ion strength in 0.1-0.3 mol/L；
(3) pH to 4.5-6.5 is adjusted with citrate again, obtains parenteral solution.
Human stem cell growth parenteral solution of the present invention has the advantages that：
(1) improve bioavilability, also can reduce dosage when maintaining equal drug effect, so as to reduce drug administration to
The side effect that patient brings；
(2) product quality is stablized, and is suitble to large-scale production and application.
Specific embodiment
The specific embodiment of the present invention is further described with reference to embodiment, the advantages and features of the present invention will
It can be with description and apparent.But these embodiments are only exemplary, do not form any restrictions to the scope of the present invention.
It it will be understood by those skilled in the art that without departing from the spirit and scope of the invention can be to technical solution of the present invention
Details and form are modified or replaced, but these modifications and replacement are each fallen in protection scope of the present invention.
Embodiment 1
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG400 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
Embodiment 2
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG600 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
Embodiment 3
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG800 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
Embodiment 4
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG200 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
Embodiment 5
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG2000 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
Embodiment 6
1000mL waters for injection are taken, pH to 5.5 is adjusted with citrate, add in human albumin 40g, stirring obtains molten
Then liquid takes the nucleotide sequence shown in 20mgSEQ ID NO.1 to be added in solution, add in PEG4000 to 15%（w/v）, stir
Mix it is uniformly mixed, 3 DEG C place 10 it is small when, add in sodium chloride, make solution ion strength in 0.2 mol/L, then with citrate tune
PH to 5.5 is saved, obtains parenteral solution.
The stability test of parenteral solution obtained by 7 Examples 1 to 6 of embodiment
Each 10 equal portions of parenteral solution of Example 1-6, every part of 10 mL are placed in a centrifuge, respectively at 37 DEG C,
When 4000rpm centrifugations 5 are small.It observes and records each group sample and the time precipitated occurs（Minute）, centrifugation end precipitation and separation weighing
Sediment weight, levels of precipitate account for the percentage table of the nucleotide sequence content in sample shown in SEQ ID NO.1 with Sediment weight
Show, it is poor that the very fast or final larger preparation stability that is considered as of levels of precipitate occurs in precipitation, as a result see the table below：
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Sedimentation time（Minute） | 195 | 230 | 190 | 160 | 165 | 150 |
| Levels of precipitate（%） | 2.1 % | 1.3% | 2.8% | 4.0 % | 3.8% | 4.5% |
Claims (2)
1. the vaccination liquid shown in a kind of SEQ ID NO.1, as shown in SEQ ID NO.1 nucleotide, human albumin,
Citrate buffer, sodium chloride and PEG600 compositions, parenteral solution pH is that 5.5, PEG600 dosages are 15%（w/v）, SEQ ID
Nucleotide shown in NO.1 is 0.02mg/mL, and for citrate content to maintain pH to 5.5, the dosage of sodium chloride is maintenance ion
Intensity is in 0.2mol/L, and human albumin's dosage is 4%（w/v）.
2. a kind of preparation method for preparing parenteral solution described in claim 1, it is characterised in that：
(1) water for injection citrate is adjusted into pH to 5.5, adds in human albumin, stirring；
(2) nucleotide shown in SEQ ID NO.1 is added in the solution of step 1, adds in PEG600, be uniformly mixed, 2-
When 5 DEG C of placements 10 are small, sodium chloride is added in, makes solution ion strength in 0.2mol/L；
(3) pH to 5.5 is adjusted with citrate again, obtains parenteral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510298631.0A CN104922698B (en) | 2015-06-03 | 2015-06-03 | Human stem cell growth parenteral solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510298631.0A CN104922698B (en) | 2015-06-03 | 2015-06-03 | Human stem cell growth parenteral solution and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104922698A CN104922698A (en) | 2015-09-23 |
| CN104922698B true CN104922698B (en) | 2018-05-29 |
Family
ID=54110339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510298631.0A Active CN104922698B (en) | 2015-06-03 | 2015-06-03 | Human stem cell growth parenteral solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922698B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114558169A (en) * | 2022-03-02 | 2022-05-31 | 北京净嘉生物科技有限公司 | Self-repairing nutrient injection and application method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102559725A (en) * | 2012-01-17 | 2012-07-11 | 广州暨南生物医药研究开发基地有限公司 | Human stem cell growth factor as well as production method and application of polyethylene glycol (PEG) modified human stem cell growth factor |
| CN103768584A (en) * | 2014-02-10 | 2014-05-07 | 济南环肽医药科技有限公司 | Relaxin injection |
-
2015
- 2015-06-03 CN CN201510298631.0A patent/CN104922698B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102559725A (en) * | 2012-01-17 | 2012-07-11 | 广州暨南生物医药研究开发基地有限公司 | Human stem cell growth factor as well as production method and application of polyethylene glycol (PEG) modified human stem cell growth factor |
| CN103768584A (en) * | 2014-02-10 | 2014-05-07 | 济南环肽医药科技有限公司 | Relaxin injection |
Non-Patent Citations (1)
| Title |
|---|
| Influence of Different Phase-Forming Parameters on the Phase Diagram of Several PEG−Salt Aqueous Two-Phase Systems;Anna Glyk et al.;《J. Chem. Eng. Data》;20140219;第59卷;第850-859页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104922698A (en) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2759508C1 (en) | Composition including exosome obtained from stem cells for induction of adipogenic differentiation, regeneration of fat tissue, skin whitening or correction of wrinkles | |
| CN109152737A (en) | Nano vesicle of binding matrix and application thereof | |
| CN103861087B (en) | Nerve growth factor is for the preparation of the purposes in treatment middle-aging male sexual disorder syndromic medicine | |
| CN108004311B (en) | Long-chain non-coding RNA NONMMUT002009 and application of overexpression plasmid thereof in diagnosis and treatment of bone system diseases | |
| Tseng et al. | An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy | |
| CN107429228B (en) | Stem cell material and preparation method thereof | |
| CN104922698B (en) | Human stem cell growth parenteral solution and preparation method thereof | |
| RU2292212C1 (en) | Conditioning medium with therapeutic effect | |
| CN106062184A (en) | Odontogenic stem cells and use of genetically modified odontogenic stem cells | |
| CN115317619A (en) | Nucleic acid nano drug carrier and application thereof | |
| KR20100080112A (en) | A composition comprising erythropoietin for promoting hair growth or inhibiting hair loss | |
| KR20160064954A (en) | Method for promoting growth of hair | |
| CN114796114B (en) | Antitumor drug micelle and preparation method and application thereof | |
| CN114404450B (en) | Temperature-sensitive type stem cell exosome in-situ gel | |
| CN111228477B (en) | HPV vaccine modified material for high-responsiveness anti-tumor immunotherapy and preparation method thereof | |
| KR101673318B1 (en) | Cell therapy composition for healing wounds comprising mesenchymal stem cell or the culture medium treated with silver nano particle | |
| US11413313B2 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising clonal stem cells | |
| CN108354896B (en) | Raltitrexed hydrogel and preparation method and application thereof | |
| EP3207927A1 (en) | Use of chlorogenic acid in manufacturing medicaments for treating oligodendroglioma | |
| CN109985061B (en) | Application of dendrobe polysaccharide in preparation of medicine for preventing and/or treating prostatic hyperplasia | |
| CN114606195A (en) | Method for enhancing sensitivity of glioma stem cells to temozolomide by low-intensity pulsed ultrasound | |
| CN117752799A (en) | Composition for bone joint degenerative diseases and preparation method thereof | |
| CN115634201A (en) | Application of manganese phosphate nano material in preparation of preparation for improving permeability of liposome chemotherapeutic drug | |
| CN116555175A (en) | Cell repair protein extract, preparation method and application thereof | |
| CN117752676A (en) | microRNA-124 nano-composite based on tetrahedral framework nucleic acid and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |